Day: November 15, 2022

Big Freedia to Join The Soul Rebels, GZA, Talib Kweli and Robert Glasper on 2023 Tour

Big Freedia, the New Orleans hip hop artist credited with bringing bounce into the mainstream, is joining a packed Bluesfest sideshow lineup for shows in Brisbane and Sydney in April 2023. The lineup includes NOLA brass band The Soul Rebels, founding member of the Wu Tang Clan GZA (aka the Genius), Black Star’s Talib Kweli and prolific jazz pianist Robert Glasper. The lineup has been […]

VentureBlick Launches Global Search for Healthcare Startups ‘Most Endorsed by the Medical Community’

SINGAPORE, Nov. 15, 2022 /PRNewswire/ — VentureBlick, a fundraising platform matching healthcare startups with medical investors, has launched its worldwide search to identify promising healthcare startups for the medical community to evaluate, advise, and fund. Only startups that receive endorsement from a large group of medical professionals with relevant domain expertise will have the chance […]

Cullen Jewellery Announces $16,500 Lab-Grown Diamond Necklace Donation for the Otis Foundation Ball

As a proud major donor of the Otis Foundation, Cullen Jewellery will participate in its Gala Ball’s live auction to raise funds for breast cancer retreats MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ — Cullen Jewellery announced today its donation of a dazzling custom-designed, 2-carat lab-grown diamond necklace in 18k yellow gold valued at $16,500 for the Otis […]

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

ROCKVILLE, Md. and SUZHOU, China, Nov. 15, 2022 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the first participant has been successfully dosed in a phase 3 clinical trial […]

Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy

— NDA acceptance takes Everest closer to making this first-in-disease treatment available for primary IgAN patients in China — China is home to the largest patient base for IgAN with estimated 5 million people with the disease and currently there is no approved treatment in the country — Nefecon is approved in the U.S. and […]

Back To Top